GDRX vs. ARWR, SMMT, ACAD, OLK, CERT, RNG, PRCT, QDEL, LTH, and AZTA
Should you be buying GoodRx stock or one of its competitors? The main competitors of GoodRx include Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), ACADIA Pharmaceuticals (ACAD), Olink Holding AB (publ) (OLK), Certara (CERT), RingCentral (RNG), PROCEPT BioRobotics (PRCT), QuidelOrtho (QDEL), Life Time Group (LTH), and Azenta (AZTA).
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and GoodRx (NASDAQ:GDRX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
GoodRx has a net margin of -1.18% compared to GoodRx's net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of 2.45% beat GoodRx's return on equity.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 1.4% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
GoodRx has higher revenue and earnings than Arrowhead Pharmaceuticals. GoodRx is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, GoodRx had 7 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 14 mentions for GoodRx and 7 mentions for Arrowhead Pharmaceuticals. GoodRx's average media sentiment score of 0.43 beat Arrowhead Pharmaceuticals' score of 0.03 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.
Arrowhead Pharmaceuticals received 461 more outperform votes than GoodRx when rated by MarketBeat users. Likewise, 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote while only 36.53% of users gave GoodRx an outperform vote.
Arrowhead Pharmaceuticals currently has a consensus target price of $50.80, suggesting a potential upside of 101.43%. GoodRx has a consensus target price of $8.78, suggesting a potential upside of 15.35%. Given GoodRx's stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than GoodRx.
Arrowhead Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
Summary
GoodRx beats Arrowhead Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get GoodRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
